METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

• Main Authors: TEW GAIK WEI, MARY KEIR
• Format: Patent
• Language: English; Japanese
• Published: 07.06.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide a biomarker for predicting responsiveness to an integrin beta 7 antagonist comprising an anti-beta 7 integrin subunit antibody and a method of using the biomarker in the treatment of gastrointestinal inflammatory disorders such as inflammatory bowel disease including ulcerative colitis and Crohn's disease.SOLUTION: The method comprises: (a) a step of measuring the level of mRNA expression of at least one gene in a biological sample from a patient with the at least one gene being selected from Integrin beta 7, Integrin alpha E, and CD 3 epsilon; (b) a step of comparing the mRNA expression level measured in step (a) to a standard level; and (c) a step of identifying patients as being potentially responsive to treatment including integrin beta 7 antagonist if the level of mRNA expression measured in (a) is higher than the standard level.SELECTED DRAWING: Figure 8 【課題】潰瘍性大腸炎及びクローン病を含む炎症性腸疾患のような胃腸炎症性障害の治療において、抗ベータ７インテグリンサブユニット抗体を含むインテグリンベータ７アンタゴニストに対する応答性を予測するためのバイオマーカーと、バイオマーカーを使用する方法の提供。【解決手段】（ａ）患者からの生物学的試料中の少なくとも一の遺伝子のｍＲＮＡ発現レベルを測定する工程であって、少なくとも一の遺伝子がインテグリンベータ７、インテグリンアルファＥ、及びＣＤ３イプシロンから選択される工程と、（ｂ）（ａ）において測定されたｍＲＮＡ発現レベルを基準レベルと比較する工程と、（ｃ）（ａ）において測定されたｍＲＮＡ発現レベルが基準レベルよりも高い場合に患者を、インテグリンベータ７アンタゴニストを含む治療に応答する可能性がある者として同定する工程とを含む、方法。【選択図】図８